Our focus

Bionure develops neuroprotectant agents to treat neurodegenerative diseases, primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis Optica (NMO). Patients affected by these rare ophthalmological diseases may become blind or, in severe cases of NMO, even die.


AON and NMO are caused when immune system reacts against its own cells in the central nervous system and produces inflammation and demyelination of the optic nerve (that can extend to spinal cord and brain in NMO). Currently, there are no neuroprotective drugs in the market for AON and NMO. Patients are treated with corticosteroids (and immunomodulators in NMO) that reduces inflammation but do not repair the damage of the nerve. AON and NMO affects more than 130,000 patients every year only in Europe and the United States.


The lead compound developed by Bionure, BN201,  has demonstrated neuroprotective activity and stimulates remyelination. Both actions combined make it a promising solution for AON and NMO patients and open a research pathway to treat other neurodegenerative diseases such as Multiple Sclerosis (MS).

Optic Neuritis

Acute Optic Neuritis (AON) is an acute, rare inflammatory disease of the optic nerve. The classic triad of inflammatory optic neuritis consists of loss of vision, periocular pain and dyschromatopsia, and is unilateral in 70% of adults (Pau et al. Eye 2011). Inflammation of the optic nerve induces significant demyelination and axonal damage, leading to permanent visual dysfunction. Acute ON is closely related to Multiple Sclerosis as it is the initial presentation in approximately 20% of cases.


Standard of Care

Patients that suffer an AON episode are currently treated with IV corticosteroids for 3-5 days. This treatment may hasten recovery due to its strong anti-inflammatory effects, but it has no effect on visual outcome, which depends on axonal damage produced in the optic nerve during the inflammation.


AON uses to happen in young people (20-40 years old). The incidence of new cases of AON has been historically estimated at 5/100,000 cases although recent epidemiological data suggests it may have increased (Martínez-Lapiscina et al. J Neurol. 2014).

Neuromyelitis Optica

Neuromyelitis Optica (NMO, also known as Devic’s disease) is a rare, chronic-relapsing inflammatory and demyelinating disease characterized mainly by recurrent and simultaneous attacks of optic neuritis and transverse myelitis. NMO is a severe and life-threatening disease as a high proportion of patients will become legally blind in one or both eyes and/or suffer from paralysis within 5 years of diagnosis. Eventually, death may occur due to severe myelitis leading to respiratory failure.


Standard of Care

NMO patients’ treatment is ineffective and includes IV corticosteroids for 3-5 days for acute relapses as well as immunosuppressive treatment to prevent relapses (e.g. azathioprine, mycophenolate or off-label rituximab and chemotherapy is often used). There are no approved efficacious therapies for preventing relapses nor for treating the disability associated with relapses.


The condition has an estimated prevalence of 1-5/100,000 and the Guthy Jackson Charitable Foundation estimates there are around 10,000 patients in the US suffering from this severe disease.

The lead compound BN201 open a research pathway to treat other neurodegenerative diseases such as Multiple Sclerosis (MS)